Click chemistry therapeutics are increasingly drawing attention from investors and big pharma.

Shasqi announced in June that it is collaborating with Johnson & Johnson Enterprise Innovation to develop cancer therapies that use click chemistry to target tumors. The deal follows a recent success for Shasqi’s click-activated drug delivery system, which has passed the first human safety trials and is now in a phase 2 clinical trial. Other groups are also preparing to test click chemistry in the clinic, raising hopes that the technique could overcome some of the limitations of existing targeting approaches such as antibody–drug conjugates.Read the full article on Nature.com